Stocks · News reference
Quanex Building Products, Concrete Pumping, SanDisk And Other Big Stocks Moving Higher On Friday
U.S. stocks mostly fell, but Quanex surged 16.6% after beating earnings and sales estimates; Reading, BBCP, Astera Labs and others also gained.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Aehr Test Systems Insider Sells $847,000 Worth of Stock
Vernon Rogers, Executive VP of Sales & Marketing at Aehr Test Systems, sold 5,994 shares worth $847,000 at $141.34 per share. The sale represents only a 3% reduction in his direct holdings, with Rogers retaining 186,232 shares valued at $27.1 million. The transaction occurred after the stock surged 695% over the past 12 months, and analysts view this as routine profit-taking rather than a sign of concern about the company's future.
Shares of semiconductor and chip companies are trading lower, possibly after Federal Reserve Chairman Warsh's comments on inflation and prices raised rate-hike concerns. The sector may be facing pressure from peer Marvell Technology, as the company pulls back after its FY28 guidance may have failed to meet investor expectations.
SanDisk Jumps 10%, Lululemon Crashes 17%: Stock Market Today
A blowout August jobs report pushed traders to price a coin-flip chance of a Federal Reserve rate hike this month, dragging the S&P 500 and Dow lower by midday Friday.
Is Marvell Technology a Millionaire-Maker Stock?
Marvell Technology has delivered extraordinary returns (180% this year, 230% over 12 months) driven by its AI infrastructure business, but the article argues it is unlikely to be a millionaire-maker stock from current levels. With 79% of revenue from data centers and strong custom silicon growth targets, Marvell has solid fundamentals. However, high expectations are already priced in, it faces intense competition from Broadcom and others, and customer concentration creates volatility risk. The stock is recommended as a quality satellite position rather than a wealth-building core holding.
8-K filing — Attovia Therapeutics, Inc. (ATTO)
Filed: 2026-09-02 AccNo: 0001193125-26-380215 Size: 388 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits